Drug spending in Canada: Recent trends and causes

Medical Care

Volumn 42, Issue 7, 2004, Pages 635-642

  Morgan, Steve ^a,b  

^a Department of Health Care and Epidemiology ^*  (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Canada; Drug costs legislation , jurisprudence; Drug costs statistics , numerical data trends

Indexed keywords

ARTICLE; CANADA; COST CONTROL; DRUG CONTROL; DRUG COST; DRUG UTILIZATION; ECONOMICS; HEALTH CARE COST; HUMAN; LEGAL ASPECT; PRESCRIPTION; STATISTICAL MODEL; STATISTICS;

CANADA; COST CONTROL; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG UTILIZATION; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMETRIC; PRESCRIPTIONS, DRUG;

EID: 3142676570     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000129494.36245.4b     Document Type: Article

References (36)

1. Drug Expenditures in Canada 1985-2002. Ottawa: Canadian Institute for Health Information; 2003.
2. Global Pharmaceutical Sales by Region, 2002. IMS Health Inc; 2003.
3. Metge C, et al. The population's use of pharmaceuticals. Med Care. 1999;37(suppl):JS42-JS59.
4. Morgan SG. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health Serv Res. 2002;37: 1243-1266.
5. Morgan SG, Agnew JD, Barer ML. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy. 2004; 68:299-307.
6. Drug Prices and Cost Drivers 1990-1997. Ottawa: Federal/Provincial/ Territorial Task Force on Pharmaceutical Prices; 1999:59.
7. PMPRB, Provincial Drug Plans Overview Report: Pharmaceutical Trends 1995/96-1999/00. 2002, Ottawa: Patented Medicine Prices Review Board; 2002:52.
8. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. Can J Clin Pharmacol. 2002;9:79-99.
9. Provincial Drug Benefit Programs, 25th ed. Ottawa: Canadian Pharmacists Association; 2003.
10. Merlis M. Explaining the Growth in Prescription Drug Spending: A Review of Recent Studies. Department of Health and Human Services Conference on Pharmaceutical Pricing Practices, Utilization and Costs; 2000.
11. 2001 Drug Trend Report. Maryland Heights, MO: Express Scripts; 2002:130.
12. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Washington, DC: National Institute for Health Care Management Foundation; 2002.
13. Anderson GM, et al. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry. 1993;30:199-207.
14. Steinberg EP, et al. Beyond survey data: a claims-based analysis of drug use and spending by the elderly. Health Aff (Millwood). 2000;19:198-211.
15. Sources of Growth in Pharmaceutical Expenditures. Waltham, MA: Brandeis University Schneider Institute for Health Policy and PCS Health Systems, Inc; 2000.
16. Managing Pharmacy Benefit Costs. Franklin Lakes, NJ: Merck-Medco; 2000.
17. Morgan SG. Statistics and drug utilization: are prescribing rates really that high? Canadian Medical Association Journal. 2001;165:1507-1508.
18. Menon D. Pharmaceutical cost control in Canada: does it work? Health Aff (Millwood). 2001;20:92-103.
19. Anis AH, Wen Q. Price regulation of pharmaceuticals in Canada. J Health Econ. 1998;17:21-38.
20. Patented Medicine Prices Review Board: Annual Report 2002. Ottawa: Patented Medicine Prices Review Board; 2003.
21. Morgan SG, Barer ML, Agnew JD. Whither seniors' Pharmacare: lessons from (and for) Canada. Health Aff (Millwood). 2003;22:49-59.
22. Garber AM. Evidence-based coverage policy. Health Aff (Millwood). 2001;20:62-82.
23. Tamblyn R. An evidence-based presentation on national standards regarding utilization. Toward a National Strategy on Drug Insurance: Challenges and Priorities. Toronto: Institute for Research on Public Policy; 2002.
24. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Canadian Medical Association Journal. 2002;166:44-47.
25. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics. 2000; 18:55-62.
26. Anis AH, Guh D, Wang X. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care. 2001;39:315-326.
27. Barer ML, Evans RG, Hertzman C. Avalanche or glacier? Health care and the demographic rhetoric. Canadian Journal on Aging. 1995;14: 193-224.
28. Evans RG, et al. Apocalypse no: population aging and the future of health care systems. Canadian Journal on Aging. 2001;20(suppl 1):160-191.
29. National Health Expenditure Trends, vol 1975/1997. Ottawa: Canadian Institute for Health Information; 1997:v.
30. Iglehart JK. Revisiting the Canadian health care system. N Engl J Med. 2000;342:2007-2012.
31. Grootendorst PL, Palfrey D, Willison D, et al. Review of the comprehensiveness of provincial drug coverage for Canadian seniors. Canadian Journal on Aging. 2003;22:33-44.
32. Rosenthal MB, et al. Demand Effects of Recent Changes in Prescription Drug Promotion. Washington, DC: The Henry J Kaiser Family Foundation; 2003:36.
33. Mintzes B, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002;324:278-279.
34. Pecorino P. Should the US allow prescription drug reimports from Canada? J Health Econ. 2002;21:699-708.
35. Goldstein A, Dewar H. Senate backs Canada drug imports. Washington Post. 2003:A07.
36. Diewert WE, Nakamura AO, eds. The Economic Theory of Index Numbers: A Survey, in Essays in Index Number Theory, vol 1. Amsterdam: Elsevier Science; 1993.